Share of Clicks for top 10 US Pharma & Biotech Research and Development brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| lilly.com | 28.7 |
| regeneron.com | 10.94 |
| gsk.com | 6.47 |
| ro.co | 4.17 |
| pfizerforall.com | 3.8 |
| abbvie.com | 3.65 |
| merck.com | 3.53 |
| sequencing.com | 2.64 |
| ziphealth.co | 1.87 |
| evenity.com | 1.56 |
| others | 32.67 |
- lilly.com - 28.7%
- regeneron.com - 10.94%
- gsk.com - 6.47%
- ro.co - 4.17%
- pfizerforall.com - 3.8%
- abbvie.com - 3.65%
- merck.com - 3.53%
- sequencing.com - 2.64%
- ziphealth.co - 1.87%
- evenity.com - 1.56%
- others - 32.67%
Copyright © Adthena. All rights reserved.
In the PPC landscape, Lilly.com leads with 28.7% click share, closely followed by Regeneron.com at 10.94%. GSK.com captures 6.47%, while ‘others’ collectively hold a significant 32.67%.
Share of Spend for the top 10 US Pharma & Biotech Research and Development brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | lilly.com | pfizerforall.com | ro.co | evenity.com | regeneron.com | scemblix.com | gsk.com | ziphealth.co | merck.com | hims.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/06/01 | 22.81% | 6.41% | 10.56% | 2.92% | 1.97% | 1.42% | 1.32% | 4.14% | 0.8% | 1.34% |
| 2026/06/02 | 27.37% | 5.45% | 8.71% | 2.35% | 4% | 3.29% | 1.48% | 4.32% | 1.34% | 2.05% |
| 2026/06/03 | 21.32% | 7.12% | 7.65% | 3.08% | 1.67% | 3.6% | 1.34% | 5.78% | 1.78% | 2.12% |
| 2026/06/04 | 27.59% | 6.35% | 8.79% | 2.46% | 2.67% | 3.23% | 1.51% | 2.47% | 1.74% | 1.72% |
| 2026/06/05 | 30.62% | 5.67% | 6.87% | 2.4% | 2.7% | 2.73% | 1.38% | 2.81% | 1.3% | 2.24% |
| 2026/06/06 | 31.58% | 4.34% | 10.22% | 2.28% | 1.84% | 2.55% | 1.24% | 3.47% | 1.28% | 3.16% |
| 2026/06/07 | 32.05% | 6.09% | 6.1% | 1.23% | 1.98% | 3.28% | 1.56% | 2.68% | 2.14% | 1.13% |
| 2026/06/08 | 36.07% | 6.31% | 6.37% | 2.25% | 1.67% | 2.53% | 1.48% | 2.01% | 1.48% | 1.46% |
| 2026/06/09 | 32.84% | 6.19% | 6.25% | 2.79% | 1.15% | 2.52% | 1.36% | 5.15% | 1.75% | 1.32% |
| 2026/06/10 | 29.2% | 5.52% | 8.32% | 2.75% | 2.52% | 2.69% | 1.13% | 2.68% | 1.68% | 2.5% |
| 2026/06/11 | 30.75% | 5.28% | 9.18% | 2% | 2.45% | 1.8% | 1.21% | 3.92% | 1.33% | 4.02% |
| 2026/06/12 | 28.85% | 5.47% | 8.77% | 2.75% | 1.51% | 2.5% | 1.14% | 3.9% | 0.96% | 4.26% |
| 2026/06/13 | 34.84% | 6.43% | 5.84% | 2.94% | 1.7% | 2.74% | 1.5% | 2.94% | 1.79% | 1.49% |
| 2026/06/14 | 31.24% | 6.39% | 8.11% | 2.96% | 2.58% | 3.62% | 1.74% | 2.21% | 1.7% | 1.4% |
| 2026/06/15 | 33.36% | 6.29% | 5.51% | 1.68% | 1.25% | 2.68% | 1.67% | 5.49% | 1.88% | 1.72% |
| 2026/06/16 | 28.34% | 6.33% | 6.47% | 2.85% | 1.61% | 3.56% | 1.59% | 3.51% | 0.9% | 1.96% |
| 2026/06/17 | 32.72% | 5.91% | 10.63% | 3.12% | 0.07% | 1.72% | 1.32% | 4.72% | 1.59% | 1.55% |
| 2026/06/18 | 27.26% | 6.12% | 9.63% | 2.54% | 0.63% | 2.5% | 1.36% | 5.05% | 1.51% | 2.03% |
| 2026/06/19 | 23.13% | 5.42% | 8.2% | 3.3% | 1.54% | 3.14% | 1.47% | 6.18% | 1.15% | 2.25% |
| 2026/06/20 | 33.97% | 6.73% | 6.9% | 3.73% | 0.02% | 3.63% | 1.62% | 0% | 2.16% | 0.21% |
| 2026/06/21 | 33.3% | 6.55% | 6.55% | 2.54% | 3.74% | 3.61% | 1.48% | 0% | 2.06% | 0.31% |
| 2026/06/22 | 37.62% | 7.31% | 3.11% | 3.17% | 2.33% | 2.44% | 1.58% | 0% | 1.22% | 0.21% |
| 2026/06/23 | 39.47% | 7.05% | 4.63% | 2.77% | 1.59% | 3.64% | 1.4% | 0% | 1.25% | 0.35% |
| 2026/06/24 | 37.4% | 7.13% | 5.37% | 1.6% | 1.86% | 2.37% | 1.79% | 0% | 1.85% | 0.05% |
| 2026/06/25 | 35.63% | 6.64% | 7.93% | 4.01% | 2.32% | 3.14% | 1.62% | 0.01% | 1.62% | 0.12% |
| 2026/06/26 | 31.74% | 8.5% | 4.97% | 3.16% | 4.36% | 3.95% | 2.05% | 0.15% | 0.64% | 0.04% |
| 2026/06/27 | 32.92% | 6.86% | 7.34% | 2.78% | 2.24% | 3.8% | 1.58% | 0% | 1.8% | 0.64% |
| 2026/06/28 | 33.29% | 7.37% | 3.66% | 4.63% | 3.97% | 3.9% | 1.75% | 0% | 2.02% | 0.02% |
| 2026/06/29 | 34.27% | 8.19% | 3.97% | 1.43% | 4.5% | 3.25% | 2.03% | 0.14% | 1.46% | 0.02% |
| 2026/06/30 | 33.89% | 8.72% | 5.91% | 4.95% | 1.96% | 1.95% | 1.72% | 1.69% | 1.11% | 0.89% |
- lilly.com
- pfizerforall.com
- ro.co
- evenity.com
- regeneron.com
- scemblix.com
- gsk.com
- ziphealth.co
- merck.com
- hims.com
Copyright © Adthena. All rights reserved.
In June 2026, lilly.com led with a peak spend share of 39.47% on the 23rd. Pfizerforall.com saw a steady rise, ending at 8.72%. Ro.co fluctuated, closing at 5.91%. Evenity.com and regeneron.com had modest gains, while scemblix.com and gsk.com maintained stability. Ziphealth.co and hims.com experienced significant drops mid-month.
Competitor Count for US Pharma & Biotech Research and Development
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/06/01 | 499 |
| 2026/06/02 | 501 |
| 2026/06/03 | 472 |
| 2026/06/04 | 505 |
| 2026/06/05 | 516 |
| 2026/06/06 | 489 |
| 2026/06/07 | 494 |
| 2026/06/08 | 491 |
| 2026/06/09 | 481 |
| 2026/06/10 | 480 |
| 2026/06/11 | 489 |
| 2026/06/12 | 471 |
| 2026/06/13 | 469 |
| 2026/06/14 | 467 |
| 2026/06/15 | 475 |
| 2026/06/16 | 479 |
| 2026/06/17 | 476 |
| 2026/06/18 | 477 |
| 2026/06/19 | 484 |
| 2026/06/20 | 466 |
| 2026/06/21 | 461 |
| 2026/06/22 | 478 |
| 2026/06/23 | 462 |
| 2026/06/24 | 460 |
| 2026/06/25 | 460 |
| 2026/06/26 | 453 |
| 2026/06/27 | 455 |
| 2026/06/28 | 444 |
| 2026/06/29 | 460 |
| 2026/06/30 | 448 |
Copyright © Adthena. All rights reserved.
June began with 499 advertisers, peaking at 516 on the 5th. A gradual decline followed, ending at 448 on the 30th.
